Cushing's syndrome medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 17: | Line 17: | ||
===Drug regimen=== | ===Drug regimen=== | ||
Indications for medical treatment of Cushing's syndrome include:<ref name="pmid22936543">{{cite journal |vauthors=van der Pas R, de Herder WW, Hofland LJ, Feelders RA |title=New developments in the medical treatment of Cushing's syndrome |journal=Endocr. Relat. Cancer |volume=19 |issue=6 |pages=R205–23 |year=2012 |pmid=22936543 |doi=10.1530/ERC-12-0191 |url=}}</ref> | |||
*Acute complications of hypercortisolism (psychosis, and infection). | |||
*Surgery pretreatment in severe cases if surgery is delayed. | |||
*Hypercortisolism after unsuccessful surgery, while awaiting control from radiotherapy. | |||
*Unresectable or metastatic tumours. | |||
*Hypercortisolism due to an occult ectopic ACTH-producing neuroendocrine tumour. | |||
Drug regimens used for the treatment of Cushing's syndrome are: <ref name="pmid26004339">{{cite journal |vauthors=Lacroix A, Feelders RA, Stratakis CA, Nieman LK |title=Cushing's syndrome |journal=Lancet |volume=386 |issue=9996 |pages=913–27 |year=2015 |pmid=26004339 |doi=10.1016/S0140-6736(14)61375-1 |url=}}</ref> | Drug regimens used for the treatment of Cushing's syndrome are: <ref name="pmid26004339">{{cite journal |vauthors=Lacroix A, Feelders RA, Stratakis CA, Nieman LK |title=Cushing's syndrome |journal=Lancet |volume=386 |issue=9996 |pages=913–27 |year=2015 |pmid=26004339 |doi=10.1016/S0140-6736(14)61375-1 |url=}}</ref> | ||
*[[ | *Drug regimen 1:[[Ketoconazole]] 400–1600 mg per day orally | ||
*[[ | *Drug regimen 2:[[Mifepristone]] 300–1200 mg per day orally | ||
*[[ | *Drug regimen 3:[[Metyrapone]] 0·5–4·5 g per day orally | ||
*[[ | *Drug regimen 4:[[Pasireotide]] 750–2400 μg per day subcutaneously injected | ||
*[[ | *Drug regimen 5:[[Cabergoline]] Up to 7 mg per week orally | ||
*[[ | *Drug regimen 6:[[Mitotane]] 3–5 g per day orally | ||
It is important to remember that the vast majority of cases of Cushing's syndrome are caused by steroid medications (such causes are described as [[iatrogenic]]) so a review of medications first, as stopping or reducing the dose can usually resolve the problem. | It is important to remember that the vast majority of cases of Cushing's syndrome are caused by steroid medications (such causes are described as [[iatrogenic]]) so a review of medications first, as stopping or reducing the dose can usually resolve the problem. | ||
Revision as of 19:49, 9 August 2017
|
Cushing's syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cushing's syndrome medical therapy On the Web |
|
American Roentgen Ray Society Images of Cushing's syndrome medical therapy |
|
Risk calculators and risk factors for Cushing's syndrome medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
The medications usually used for the treatment of Cushing's syndrome are Pasireotide, Cabergoline, Ketoconazole and Metyrapone.
Medical therapy
The medications usually used for the treatment of Cushing's syndrome are:[1]
Drug regimen
Indications for medical treatment of Cushing's syndrome include:[2]
- Acute complications of hypercortisolism (psychosis, and infection).
- Surgery pretreatment in severe cases if surgery is delayed.
- Hypercortisolism after unsuccessful surgery, while awaiting control from radiotherapy.
- Unresectable or metastatic tumours.
- Hypercortisolism due to an occult ectopic ACTH-producing neuroendocrine tumour.
Drug regimens used for the treatment of Cushing's syndrome are: [1]
- Drug regimen 1:Ketoconazole 400–1600 mg per day orally
- Drug regimen 2:Mifepristone 300–1200 mg per day orally
- Drug regimen 3:Metyrapone 0·5–4·5 g per day orally
- Drug regimen 4:Pasireotide 750–2400 μg per day subcutaneously injected
- Drug regimen 5:Cabergoline Up to 7 mg per week orally
- Drug regimen 6:Mitotane 3–5 g per day orally
It is important to remember that the vast majority of cases of Cushing's syndrome are caused by steroid medications (such causes are described as iatrogenic) so a review of medications first, as stopping or reducing the dose can usually resolve the problem.
References
- ↑ 1.0 1.1 Lacroix A, Feelders RA, Stratakis CA, Nieman LK (2015). "Cushing's syndrome". Lancet. 386 (9996): 913–27. doi:10.1016/S0140-6736(14)61375-1. PMID 26004339.
- ↑ van der Pas R, de Herder WW, Hofland LJ, Feelders RA (2012). "New developments in the medical treatment of Cushing's syndrome". Endocr. Relat. Cancer. 19 (6): R205–23. doi:10.1530/ERC-12-0191. PMID 22936543.